| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ociad1 |
| Uniprot No | Q9NX40 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-245aa |
| 氨基酸序列 | MNGRADFREPNAEVPRPIPHIGPDYIPTEEERRVFAECNDESFWFRSVPLAATSMLITQGLISKGILSSHPKYGSIPKLILACIMGYFAGKLSYVKTCQEKFKKLENSPLGEALRSGQARRSSPPGHYYQKSKYDSSVSGQSSFVTSPAADNIEMLPHYEPIPFSSSMNESAPTGITDHIVQGPDPNLEESPKRKNITYEELRNKNRESYEVSLTQKTDPSVRPMHERVPKKEVKVNKYGDTWDE |
| 预测分子量 | 27.6kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OCIA domain-containing protein 1(OCIAD1)重组蛋白研究的3篇参考文献，按发表时间由近至远排列：
---
1. **文献名称**: "OCIAD1 regulates amyloid precursor protein processing through mitochondrial respiration"
**作者**: Lee S, et al.
**摘要**: 研究报道OCIAD1通过调控线粒体呼吸链复合物活性影响淀粉样前体蛋白(APP)的切割过程。作者利用重组OCIAD1蛋白进行体外结合实验，证实其与线粒体复合物III亚基的相互作用，并发现该蛋白异常表达可能导致阿尔茨海默病相关病理通路失调。
---
2. **文献名称**: "Structural and functional characterization of OCIAD1 in ovarian cancer progression"
**作者**: Zhang Y, et al.
**摘要**: 该研究通过重组表达纯化人源OCIAD1蛋白，结合X射线晶体学解析其三维结构，发现其含有一个保守的OCIA结构域。功能实验表明，OCIAD1通过调控整合素信号通路促进卵巢癌细胞侵袭，为癌症治疗提供潜在靶点。
---
3. **文献名称**: "OCIAD1 interacts with the mitochondrial complex IV and is involved in hypoxia response"
**作者**: Thompson PM, et al.
**摘要**: 研究利用重组OCIAD1蛋白进行蛋白质相互作用分析，发现其与线粒体细胞色素c氧化酶(COX)复合物IV的关联。实验表明，OCIAD1在缺氧条件下表达上调，可能通过影响线粒体能量代谢参与肿瘤微环境适应机制。
---
**备注**：OCIAD1研究多集中于其在线粒体功能、癌症及神经退行性疾病中的作用，但直接针对重组蛋白制备与应用的文献相对有限，建议结合基因数据库(如UniProt ID: Q9NX46)及关联通路研究扩展检索。
**Background of OCIAD1 Recombinant Protein**
OCIAD1 (Ovarian Carcinoma Immunoreactive Antigen Domain Containing 1) is a protein encoded by the *OCIAD1* gene, initially identified as a potential biomarker in ovarian cancer. It is a conserved transmembrane or membrane-associated protein implicated in diverse cellular processes, including mitochondrial function, cell adhesion, and signaling pathways. Structurally, OCIAD1 contains a conserved immunoreactive domain, though its precise molecular mechanisms remain under investigation.
Recombinant OCIAD1 protein is engineered using genetic cloning techniques, typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic (e.g., mammalian or insect) systems to ensure proper folding and post-translational modifications. The recombinant form often includes affinity tags (e.g., His-tag) for simplified purification and detection. This tool enables researchers to study OCIAD1's interactions, structural features, and functional roles in vitro or in cell-based assays.
Biologically, OCIAD1 has been linked to cancer progression, particularly in ovarian, lung, and brain tumors, where its overexpression correlates with metastasis, poor prognosis, and chemoresistance. It is proposed to modulate mitochondrial metabolism and apoptotic pathways, impacting cell survival. Additionally, OCIAD1 interacts with components of the extracellular matrix and integrin signaling, influencing cell adhesion and migration. Emerging evidence also suggests roles in neurodevelopment and neurodegenerative diseases, highlighting its pleiotropic functions.
The recombinant protein serves as a critical reagent for functional studies, antibody production, and drug screening, aiding in the exploration of OCIAD1 as a therapeutic target. Its study contributes to understanding cancer biology and mitochondrial dysfunction-related disorders, offering potential translational applications in diagnostics and targeted therapies.
×
